Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis
Molecular Neurobiology · 2025-04 · 62 (4) · 4391-4419
DOI: 10.1007/s12035-024-04543-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Neurobiology, online erschienen am 24.10.2024. Verfasst von Zaida L Almeida und 2 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry Department and Coimbra Chemistry Centre - Institute of Molecular Sciences (CQC-IMS), University of Coimbra, 3004-535, Coimbra, Portugal. za…. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 286 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia, Universidade de Coimbra.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is the most common form of dementia around the world (~ 65%). Here, we portray the neuropathology of AD, biomarkers, and classification of amyloid plaques (diffuse, non-cored, dense core, compact). Tau pathology and its involvement with Aβ plaques and cell death are discussed. Amyloid cascade hypotheses, aggregation mechanisms, and molecular species formed in vitro and in vivo (on- and off-pathways) are described. Aβ42/Aβ40 monomers, dimers, trimers, Aβ‐derived diffusible ligands, globulomers, dodecamers, amylospheroids, amorphous aggregates, protofibrils, fibrils, and plaques are characterized (structure, size, morphology, solubility, toxicity, mechanistic steps). An update on AD-approved drugs by regulatory agencies, along with new Aβ-based therapies, is presented. Beyond prescribing Aβ plaque disruptors, cholinergic agonists, or NMDA receptor antagonists, other therapeutic strategies (RNAi, glutaminyl cyclase inhibitors, monoclonal antibodies, secretase modulators, Aβ aggregation inhibitors, and anti-amyloid vaccines) are already under clinical trials. New drug discovery approaches based on “designed multiple ligands”, “hybrid molecules”, or “multitarget-directed ligands” are also being put forward and may contribute to tackling this highly debilitating and fatal form of human dementia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemistry Department and Coimbra Chemistry Centre - Institute of Molecular Sciences (CQC-IMS), University of Coimbra, 3004-535, Coimbra, Portugal. zalmeida@qui.uc.pt.
- Chemistry Department and Coimbra Chemistry Centre - Institute of Molecular Sciences (CQC-IMS), University of Coimbra, 3004-535, Coimbra, Portugal. daniela.vaz@ipleiria.pt.
- School of Health Sciences, Polytechnic Institute of Leiria, 2411-901, Leiria, Portugal. daniela.vaz@ipleiria.pt.
- LSRE-LCM, Laboratory of Separation and Reaction Engineering and Laboratory of Catalysis and Materials, Leiria, 2411-901, Portugal. daniela.vaz@ipleiria.pt.
- ALiCE - Associate Laboratory in Chemical Engineering, University of Porto, 4200-465, Porto, Portugal. daniela.vaz@ipleiria.pt.
- Chemistry Department and Coimbra Chemistry Centre - Institute of Molecular Sciences (CQC-IMS), University of Coimbra, 3004-535, Coimbra, Portugal. brito@ci.uc.pt.
Förderung
- Fundação para a Ciência e a Tecnologia
- Universidade de Coimbra
Zitieren
APA
Almeida, Z. L., Vaz, D. C., & Brito, R. M. M. (2025). Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis. Molecular Neurobiology, 62(4), 4391-4419. https://doi.org/10.1007/s12035-024-04543-4
Vancouver
Almeida ZL, Vaz DC, Brito RMM. Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis. Molecular Neurobiology. 2025;62(4):4391-4419. doi:10.1007/s12035-024-04543-4
BibTeX
@article{Almeida2025,
author = {Almeida, Zaida L and Vaz, Daniela C and Brito, Rui M M},
title = {Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis},
journal = {Molecular Neurobiology},
year = {2025},
volume = {62},
number = {4},
pages = {4391--4419},
doi = {10.1007/s12035-024-04543-4}
}
EUVIMED